Last week, the House of Representatives passed an infrastructure legislation that includes provisions which will permit researchers to conduct research on the cannabis that consumers purchase from state-legal dispensaries.
This bill, which has been advanced to President Joe Biden’s desk, also encourages states that have enacted laws to legalize marijuana to educate individuals on impaired driving. A study that was funded by the federal government found that the amount of THC in an individual’s system after they had consumed cannabis wasn’t a reliable predictor of impairment.
Despite this finding, however, the measure directs that the transportation secretary work with the secretary of health and human services and the attorney general to compile a public report in two years, which should include recommendations on permitting researchers to access retail-level cannabis to conduct research on impaired driving.
A provision in the legislation also states that the report should contain a recommendation on the establishment of a national clearinghouse, which will gather and distribute strains and samples of cannabis for scientific research, including cannabis and products containing cannabis that is lawfully available to consumers or patients on a retail basis in a particular state
In another interview, Sen. John Hickenlooper stated that citizens in the country supported the legalization of cannabis, noting that the measure being enacted into law would be a step forward toward researching how the government could regulate marijuana-impaired driving accurately as well as safely.
This move by the House comes as Democratic legislators in Congress work on advancing different cannabis legalization measures, including a federal measure that was approved in September by the House Judiciary Committee.
Separately, the House Veterans’ Affairs Committee also approved an initiative last week that directs the Department of Veterans Affairs to carry out clinical trials on the medical benefits of cannabis for military veterans with chronic pain and post-traumatic stress disorder.
Additionally, the DEA recently suggested that a significant increase be made to the production of psilocybin and cannabis for research purposes. The agency’s objective is to assist in the development of new therapeutic medications, which will be federally approved.
The agency has also released a notice announcing that it plans to approve the applications of different firms, which will allow said companies to become federally authorized marijuana manufacturers. The marijuana will be used for research purposes.
In an interview, Nora Volkow, director of the National Institute on Drug Abuse, asserted that allowing researchers to study marijuana from state-licensed dispensaries was scientifically valuable.
These different efforts by advocates point to the possibility that sooner rather than later, marijuana may be decriminalized federally and industry players such as American Cannabis Partners will have fewer hoops to jump through as they grow their operations beyond state borders.
NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
